DailyIQ
|
Sector:Basic MaterialsAll sectors
Last updated 3 minutes ago

FMC·FMC Corporation

$.
+. (+.%)
After Hours
High
$11.15
Open
$10.98
Market Cap
1.36B
52W High
$44.06
Low
$10.68
P. Close
$10.91
P/E
-
52W Low
$10.68
Fwd P/E
5.23
DailyIQ Est.
$16.08
Technical Score (1D)
14
SELL
News Sentiment
61
BULLISH
FMC’s first global regulatory submission for rimisoxafen to the U.S. Environmental Protection Agency marks a key step toward U.S. market access for the next‑generation weed‑control active ingredient. The filing expands the company’s footprint beyond the EU, where rimisoxafen has already been approved, and signals a potential new revenue stream in the U.S. crop‑protection market. Because the dossier covers corn, soybean, sunflower and select pulse crops, it directly addresses the rising weed‑resistance pressure in major row‑crop regions, positioning FMC to capture a larger share of that segment. The outcome of the EPA review will therefore influence short‑term revenue projections and could accelerate the company’s growth narrative. Traders should monitor the EPA’s review milestones and any guidance issued in the next 1–10 trading days. In parallel, FMC’s $400 million minority equity investment from Tessenderlo Group will reduce debt by roughly $1 billion, improving leverage and freeing capital for future growth initiatives. Watch how the capital is deployed—whether for R&D, acquisitions or further debt repayment—and its impact on the company’s balance sheet in the upcoming earnings release. Finally, the spike in options open interest and implied volatility suggests market participants are bracing for a sizable move, so keep an eye on the next earnings report and any regulatory updates that could trigger a shift in sentiment.
Earnings Summary
FMC Corporation is a global agricultural sciences company that develops, markets, and sells crop protection products such as insecticides, herbicides, and fungicides, serving farmers worldwide across North and Latin America, Europe, the Middle East, Africa, and Asia within the Basic Materials sector and Agricultural Inputs industry. In the most recent four quarters, FMC consistently beat earnings estimates, with Q4 2024 EPS of $1.79 versus $1.60 expected, Q1 2025 EPS of $0.18 versus $0.09, Q2 2025 EPS of $0.69 versus $0.62, and Q3 2025 EPS of $0.89 versus $0.85; only Q4 2025 saw a slight EPS miss at $1.20 versus $1.21. Revenue, however, has been volatile: Q4 2024 generated $1.22 billion, dropping 35% to $791 million in Q1 2025, rising 32% to $1.05 billion in Q2 2025, falling 48% to $542 million in Q3 2025, and then nearly doubling to $1.08 billion in Q4 2025, though still $79 million below the $1.16 billion estimate. This pattern shows a four‑quarter streak of EPS beats but inconsistent revenue growth, with Q4 2025 revenue falling short of guidance. Historically, FMC has maintained a strong earnings beat streak, with EPS exceeding estimates in each of the last five quarters, while revenue growth has been uneven, reflecting seasonal demand swings and product mix changes. Recent news highlights a first global regulatory submission for rimisoxafen to the U.S. EPA, potentially opening a new U.S. revenue stream and addressing weed‑resistance pressures in major row‑crop markets, and a $400 million minority equity investment from Tessenderlo Group that will reduce debt by roughly $1 billion, improving leverage and freeing capital for growth initiatives; these developments could influence short‑term revenue projections and balance‑sheet strength. Investors should watch for EPA review milestones and any guidance on rimisoxafen’s U.S. approval, monitor how the capital from Tessenderlo is deployed—whether toward R&D, acquisitions, or debt repayment—and track subsequent revenue guidance and debt metrics in the next earnings release, as these factors will be key to assessing FMC’s near‑term financial trajectory.

EPS

EstBeatMiss
$-0.57$-0.06$0.44$0.94$1.45Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.22 - -
Q1'26$-0.34$-0.23+31.4%
Q4'25$1.21$1.20-1.2%
Q3'25$0.85$0.89+4.1%
Q2'25$0.62$0.69+11.2%
Q1'25$0.09$0.18+94.7%

Revenue

EstBeatMiss
$449M$651M$852M$1.1B$1.3BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$914M - -
Q1'26$752M$759M+0.9%
Q4'25$1.2B$1.1B-6.8%
Q3'25 - $542M -
Q2'25 - $1.1B -
Q1'25 - $791M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

FMC Stock Snapshot

FMC is currently trading at $10.90, giving FMC Corporation a market cap of 1.36B. Today's range spans $10.68–$11.15, with shares opening at $10.98 and moving down $0.01 (0.1%) from the prior close. DailyIQ's technical score sits at 14/100 (SELL) with a news sentiment reading of 61/100.

Over the past year FMC has traded between $10.68 and $44.06 - the current price is +2.1% off the 52-week low and -75.3% from the high. 23 analysts cover the stock with a Hold consensus and a mean 12-month target of $16.13 (range $12.00–$26.00), implying upside of +48.0%.

Mean-reversion potential exists for FMC - but it needs a catalyst. 14/100 (SELL), bullish sentiment (61/100), price $10.90 (near 52-week lows in $10.68–$44.06). At 1.36B in Basic Materials market cap, small-cap stocks in bearish phases don't typically recover on technicals alone - they need a news event, earnings surprise, or sector catalyst to shift the momentum. Without one, the SELL setup tends to persist longer than fundamental analysis would suggest.

The absence of strong institutional sponsorship makes FMC's SELL signal (14/100) more consequential than the same signal in a larger name — at 1.36B in Basic Materials market cap, there are fewer natural buyers to absorb selling pressure, which means the $10.68–$44.06 range's lower bound becomes a sharper test of the thesis. Sentiment at 61/100 (bullish) and price at $10.90 (near 52-week lows) don't yet suggest stabilization is imminent.